Connection

Gionata Fiorino to Colitis, Ulcerative

This is a "connection" page, showing publications Gionata Fiorino has written about Colitis, Ulcerative.
Connection Strength

2.124
  1. Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. J Crohns Colitis. 2019 Mar 30; 13(4):417-423.
    View in: PubMed
    Score: 0.383
  2. JAK inhibitors: Novel developments in management of ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:89-93.
    View in: PubMed
    Score: 0.361
  3. The safety of biological pharmacotherapy for the treatment of ulcerative colitis. Expert Opin Drug Saf. 2017 Apr; 16(4):437-443.
    View in: PubMed
    Score: 0.332
  4. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis. 2017 02; 23(2):233-243.
    View in: PubMed
    Score: 0.330
  5. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. Immunotherapy. 2019 05; 11(7):565-575.
    View in: PubMed
    Score: 0.095
  6. Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. J Crohns Colitis. 2018 Nov 28; 12(12):1385-1391.
    View in: PubMed
    Score: 0.094
  7. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study. Dig Liver Dis. 2019 04; 51(4):510-515.
    View in: PubMed
    Score: 0.093
  8. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study. Inflamm Bowel Dis. 2018 10 12; 24(11):2442-2451.
    View in: PubMed
    Score: 0.093
  9. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. Expert Opin Investig Drugs. 2018 Jul; 27(7):623-629.
    View in: PubMed
    Score: 0.091
  10. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opin Investig Drugs. 2018 07; 27(7):595-599.
    View in: PubMed
    Score: 0.091
  11. Can IL-23 be a good target for ulcerative colitis? Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:95-102.
    View in: PubMed
    Score: 0.090
  12. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis. 2014 Nov; 8(11):1548-50.
    View in: PubMed
    Score: 0.069
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.